



Global Product Development

02 August 2021

Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

Re: BLA 125742

COVID-19 mRNA Vaccine (BNT162/PF-07302048)

Preliminary requested changes and comments on the draft Package Insert for COMIRNATY

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 19 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥ 16 years of age.

The present submission provides responses and updates to the Agency's 28 July 2021 Preliminary requested changes on the draft package insert for COMIRNATY. The updated draft package insert is provided in Module 1.14.1:

- Track change ([Word](#))
- Annotated ([PDF](#))
- Clean copy ([PDF](#) and [Word](#))

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at elisa.harkinstull@pfizer.com.

Sincerely,

Elisa Harkins
Global Regulatory Lead
Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.